EXAS stock information

Sector:

Healthcare

Description:

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation website

Current Price

$83.84

RSI

71.04

Market Capitalization:

11.4B

Beta:

1.157

Volume:

1,477,564

Analyst Target Price:

$ 112.81

Economiic Fair Price:

Earnings DateNovember 03, 2022

Report DateNovember 03, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS-3.476

Profit Margin-33.70 %

Revenue Per Share TTM10.31

Return On Equity TTM-0.212

YoY Revenue Growth (TTM)

14.30 %

YoY Pre Tax Income Growth (TTM)

23.98 %

YoY Free Cash Flow (TTM)

-303.68 %

QoQ Revenue Growth

14.61 %

QoQ Pre Tax Income Growth

11.08 %

QoQ Free Cash Flow Growth

-7.43 %

2021 Revenue

$ 1.8B

18.49 %

2020 Revenue

$ 1.5B

70.19 %

2019 Revenue

$ 876.3M

92.82 %

2018 Revenue

$ 454.5M

70.86 %

2017 Revenue

$ 266M

167.66 %

2016 Revenue

$ 99.4M

2021 Free Cash Flow

$ -238M

-429.96 %

2020 Free Cash Flow

$ 72.1M

125.15 %

2019 Free Cash Flow

$ -286.8M

-30.37 %

2018 Free Cash Flow

$ -220M

-56.07 %

2017 Free Cash Flow

$ -141M

2.73 %

2016 Free Cash Flow

$ -144.9M

2021 Pre Tax Income

$ -842.5M

1.70 %

2020 Pre Tax Income

$ -857.1M

-218.80 %

2019 Pre Tax Income

$ -268.9M

-53.58 %

2018 Pre Tax Income

$ -175.1M

-52.78 %

2017 Pre Tax Income

$ -114.6M

31.47 %

2016 Pre Tax Income

$ -167.2M

Exact Sciences Corporation(EXAS)